SILENCE THER. (SLN)

 

Latest News

Post year end business update

RNS Number: 1629B Silence Therapeutics PLC 08 January 2018 Post year end business update 8 January 2018 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces a post year end update. Arrowhead dis...

Silence Therapeutics sells more shares in Arrowhead

Silence Therapeutics has sold a further part of its holding in Arrowhead Pharmaceuticals. Since an announcement on 11 D...

Further Partial Disposal - Arrowhead common shares

Statement regarding the disposal of a company or assets

Second Price Monitoring Extn

All News

DateHeadlineSource
08-01-18Post year end business updateRNS
28-12-17Silence Therapeutics sells more shares in ArrowheadStockMarketWire
28-12-17Further Partial Disposal - Arrowhead common sharesRNS
15-12-17Second Price Monitoring ExtnRNS
15-12-17Price Monitoring ExtensionRNS
14-12-17Price Monitoring ExtensionRNS
14-12-17Broker Forecast - Peel Hunt issues a broker note on Silence Therapeutics PLCStockMarketWire
11-12-17Further Partial Disposal - Arrowhead common sharesRNS
04-12-17Silence Therapeutics sells some Arrowhead sharesStockMarketWire
04-12-17Partial Disposal of Arrowhead common sharesRNS
20-11-17Silence Therapeutics provides litigation updateStockMarketWire
20-11-17Update on litigation mattersRNS
14-11-17Capital Markets DayRNS
03-11-17Silence Therapeutics provides litigation updateStockMarketWire
03-11-17Update on Litigation MattersRNS
02-11-17Second Price Monitoring ExtnRNS
02-11-17Price Monitoring ExtensionRNS
26-10-17Holding(s) in CompanyRNS
24-10-17Holding(s) in CompanyRNS
19-10-17Holding(s) in CompanyRNS
18-10-17Holding(s) in CompanyRNS
18-10-17Silence Therapeutics granted US patentsStockMarketWire
18-10-17Further US patents grantedRNS
17-10-17Serving of claim in the UK High CourtRNS
16-10-17Silence Therapeutics appoints new chairmanStockMarketWire
16-10-17Appointment of Non-Executive ChairRNS
11-10-17Silence Therapeutics granted US patentStockMarketWire
11-10-17Key US patent grantedRNS
06-10-17Holding(s) in CompanyRNS
28-09-17Holding(s) in CompanyRNS
27-09-17Holding(s) in CompanyRNS
27-09-17Holding(s) in CompanyRNS
26-09-17Holding(s) in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
20-09-17Second Price Monitoring ExtnRNS
20-09-17Price Monitoring ExtensionRNS

RSS feeds

  • Editorial news feed for LSE:SLN Editorial
  • Regulatory news feed for LSE:SLN Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account